ESTRO 2025 - Abstract Book

S4208

RTT - Patient experience and quality of life

ESTRO 2025

Conclusion: While image-based response monitoring offers opportunities to reduce patient anxiety and enhance outcomes, systemic barriers, including resource constraints, must be addressed to enable successful implementation. These findings provide actionable insights to guide future technology development and improve radiotherapy care.

Keywords: Head and Neck, Radiotherapy

References: 1 Cancer Research UK (2019). Available at: CRUK Accessed: 19 November 2024. 2 Owens, D., Paleri, V. & Jones, A. Head and neck cancer explained: an overview of management pathways. Br Dent J 233 , 721–725 (2022). https://doi.org/10.1038/s41415-022-5199-1 3 Anderson G, Ebadi M, Vo K, Novak J, Govindarajan A, Amini A. An Updated Review on Head and Neck Cancer Treatment with Radiation Therapy. Cancers (Basel). 2021 Sep 30;13(19):4912. doi: 10.3390/cancers13194912. PMID: 34638398; PMCID: PMC8508236. 4 Public Health England (2020). Chemotherapy, Radiotherapy and Surgical Tumour Resections in England. Available at: GOV UK. Accessed: 19 November 2024.

4151

Digital Poster Quality of life in vaginal brachytherapy for cervical carcinoma. FATIMA ZAHRA CHRAA, rachida laraichi, chadia ezzouitina, karima nouni, amine lachgar, hanane el kacemi, tayeb kebdani, khalid hassouni radiotherapy, institut national d'oncologie, rabat, Morocco Purpose/Objective: This study aimed to evaluate the clinical outcomes and quality of life (QoL) of patients with stage I cervical cancer (CC-I) receiving adjuvant vaginal brachytherapy (VB) at the National Institute of Oncology in Rabat, Morocco, between January 2024 and June 2024. Material/Methods: This retrospective study included 50 patients diagnosed with cancer treated with vaginal brachytherapy in the Radiotherapy Department of the National Institute of Oncology. The mean age of the patients was 72 years (range 65-85). Pathologic stage and grade were as follows: IIB (n=7), IIIB (n=30), IIIC 1(n=8), and IVA (n=5). Patients were treated with either 3D vaginal brachytherapy to a total dose of 28 Gy at 5mm depth from the applicator surface in 4 weekly fractions (4x7Gy) after 23 fractions of external radiotherapy (23x2Gy) with concomitant chemotherapy. The study assessed the impact of pathologic stage and grade on loco-regional relapse (LRR), metastases, and tumor related mortality. Patient-reported vaginal toxicity and QoL were evaluated using the EORTC QLQ-C30 and QLQ CX24 questionnaires. Statistical analysis was performed using the Kaplan-Meier method, Logrank test, and Chi square test. Results: After a median follow-up of 52 months (range 8-96), the 5-year disease-free survival (DFS), local relapse-free survival (LRFS), and pelvic relapse-free survival (PRFS) rates were 83%, 100%, and 89%, respectively. The PRFS rate was lower in grade 3 tumors compared to grade 1-2 tumors (78% vs 92%, p=NS). No patients experienced grade 3 or 4 toxicity. Chronic vaginal toxicity (Grade 1-2) was observed in 40% of patients. The EORTC QLQ-C30 questionnaire revealed excellent QoL scores, with functional scores above 75% and symptom scores below 25%. The global health status and QoL scale were 80%, indicating “good” to “very good” QoL. The QLQ-CX24 questionnaire identified sexual enjoyment and pain as the most problematic areas, with mean scores of 10% and 35%, respectively.